NHS England takes tough stance on homeopathy
pharmafile | July 24, 2017 | News story | Sales and Marketing | NHS England, biotech, drugs, pharma, pharmaceutical
Homeopathy is one of the most controversial subjects within the healthcare system and NHS England has outlined its stance by proposing cutting funding to the medicine. Beyond this, other over-the-counter (OTC) treatments, such as cold and flu medicine, would also no longer be available on prescription as part of NHS England’s action plan.
The decisions were reached as the NHS struggles to find savings, with drug prescription costs being identified as a possible money saver for the service. In total, 18 treatments will no longer be available on prescription that could save £141 million annually.
No longer having homeopathic treatments available of prescription was widely welcomed by the scientific community, Simon Stevens, NHS England’s Chief Executive, in particular did not pull any punches in his assessment, labelling the treatments: “at best a placebo and a misuse of scarce NHS funds”.
Herbal medicines cost the service £100,009 and ‘homeopathy items’ were found to cost £92,412, in 2016. This decision also extends to other areas, such as gluten-free food, which used to be a niche therapeutic area but has become rapidly mainstream as part of a dietary choice. The service reasoned that now products, such as gluten-free bread, would be available cheaper in non-OTC areas, saving prescription costs to the service £26 million per year.
The areas of these cuts that proved controversial were the prescriptions that are for a medical purpose but are more cheaply and widely available OTC, such as prescriptions for cold medicine and sun cream.
This was criticised as likely to discriminate against those not able to afford to purchase such items. This stance is somewhat controversial given that cold remedies generally only mask symptoms rather than alleviate the illness itself. However, it was criticised as introducing ‘ability to pay’ as a barrier to some people receiving treatments.
Don Redding, director of policy at National Voices, said: “NHS England point out that some of these treatments can be bought OTC at a cheaper price than the NHS can prescribe them. That raises questions about NHS procurement and negotiations with industry. It is not a problem to pass on to the poorest patients.”
The major cost saving measures from the proposed cuts would be £34.8 million saved on Liothryonine, used for underactive thyroid, and antidepressant Trimipramine, saving £19.8 million.
The proposals are a part of a consultation process that will run until October, at which point a decision will be reached regarding funding.
Ben Hargreaves
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
